Figure 4.

Inhibition of GlcCer synthase or GlcCer degradation in HeLa, GlcCer synthase inhibition in HeLa GBA^KO, or GlcCer degradation in H1703 did not affect EMT marker levels. (a) MonoHex-Cer mass spectrometry analysis of HeLa cells treated with DMSO (0.01% w/v), 1 µM eliglustat tartrate, or 35 µM CβE for 15 days with biweekly medium changes; N = 3. (b,c) Immunoblots (b) and corresponding densitometry (c) analysis with the indicated antibodies of cells treated in panel (a). (d–f) Immunoblots (d), corresponding densitometry (e), and mass spectrometry (f) analysis of HeLa GBA^KO cells treated with DMSO (0.01% w/v) or 1 µM eliglustat tartrate for 15 days with biweekly medium changes. (g) Immunoblots and corresponding densitometry analysis of H1703 cells treated with treated with DMSO (0.01% w/v) or 35 µM CβE for 10 days with biweekly medium changes; N = 3 all cell lines. Plots are bar graphs with the mean ± SEM. In (a,c,e,f), statistical tests were performed with ANOVA and multiple comparisons; in (g) t-test (Prism) was performed: ns, not significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.005. Blots were quantified with ImageJ.